VAXCYTE, INC. Increase (Decrease) in Accounts Payable
VAXCYTE, INC. (PCVX) reported Increase (Decrease) in Accounts Payable of $31.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- VAXCYTE, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $31.55M, a 231.28% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$269.00K.
- VAXCYTE, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $21.67M, a 30.80% decline year-over-year.
- VAXCYTE, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $17.88M, a 115.10% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in accounts payable for fiscal 2025 was $19.91M, a 42.44% decline from fiscal 2024.
- VAXCYTE, INC. increase (decrease) in accounts payable for fiscal 2024 was $34.58M, a 208.10% increase from fiscal 2023.
- VAXCYTE, INC. increase (decrease) in accounts payable for fiscal 2023 was $11.22M, a 287.60% increase from fiscal 2022.
- VAXCYTE, INC. increase (decrease) in accounts payable for fiscal 2022 was $2.90M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $31.29M 10-Q · filed 2026-08-05 | $52.95M derived: sum of 3 quarters · filed 2026-08-05 | $70.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$269.00K 10-Q · filed 2026-05-06 | $21.40M derived: sum of 2 quarters · filed 2026-05-06 | $39.27M derived: sum of 3 quarters · filed 2026-05-06 | $48.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $21.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $39.54M derived: sum of 2 quarters · filed 2026-02-24 | $49.07M derived: sum of 3 quarters · filed 2026-08-05 | $19.91M 10-K · filed 2026-02-24 |
| 2025-09-30 | $17.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $27.40M derived: sum of 2 quarters · filed 2026-08-05 | -$1.76M 10-Q · filed 2025-11-04 | $29.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $9.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$19.64M 10-Q · filed 2026-08-05 | $11.67M derived: sum of 3 quarters · filed 2026-08-05 | $19.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$29.16M 10-Q · filed 2026-05-06 | $2.15M derived: sum of 2 quarters · filed 2026-05-06 | $10.46M derived: sum of 3 quarters · filed 2026-05-06 | -$251.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $31.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $39.62M derived: sum of 2 quarters · filed 2026-02-24 | $28.91M derived: sum of 3 quarters · filed 2026-02-24 | $34.58M 10-K · filed 2026-02-24 |
| 2024-09-30 | $8.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.40M derived: sum of 2 quarters · filed 2025-11-04 | $3.27M 10-Q · filed 2025-11-04 | $9.75M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$10.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$5.04M 10-Q · filed 2025-08-06 | $1.44M derived: sum of 3 quarters · filed 2026-02-24 | $2.14M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $5.67M 10-Q · filed 2025-05-07 | $12.15M derived: sum of 2 quarters · filed 2026-02-24 | $12.85M derived: sum of 3 quarters · filed 2026-02-24 | $15.11M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $6.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.17M derived: sum of 2 quarters · filed 2026-02-24 | $9.44M derived: sum of 3 quarters · filed 2026-02-24 | $11.22M 10-K · filed 2026-02-24 |
| 2023-09-30 | $694.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $2.96M derived: sum of 2 quarters · filed 2024-11-05 | $4.75M 10-Q · filed 2024-11-05 | $8.22M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.05M 10-Q · filed 2024-08-06 | $7.52M derived: sum of 3 quarters · filed 2025-02-25 | $6.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.79M 10-Q · filed 2024-05-08 | $5.26M derived: sum of 2 quarters · filed 2025-02-25 | $3.91M derived: sum of 3 quarters · filed 2025-02-25 | $6.62M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.12M derived: sum of 2 quarters · filed 2025-02-25 | $4.83M derived: sum of 3 quarters · filed 2025-02-25 | $2.90M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.36M derived: sum of 2 quarters · filed 2023-11-06 | -$575.00K 10-Q · filed 2023-11-06 | -$18.65M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $779.00K 10-Q · filed 2023-08-08 | -$17.29M derived: sum of 3 quarters · filed 2024-02-27 | -$15.79M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$1.93M 10-Q · filed 2023-05-08 | -$20.00M derived: sum of 2 quarters · filed 2024-02-27 | -$18.51M derived: sum of 3 quarters · filed 2024-02-27 | -$16.59M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$18.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$16.57M derived: sum of 2 quarters · filed 2024-02-27 | -$14.65M derived: sum of 3 quarters · filed 2024-02-27 | -$12.47M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.42M derived: sum of 2 quarters · filed 2022-11-07 | $5.60M 10-Q · filed 2022-11-07 | $24.37M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $4.10M 10-Q · filed 2022-08-08 | $22.88M derived: sum of 3 quarters · filed 2023-02-27 | $31.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.19M 10-Q · filed 2022-05-09 | $20.96M derived: sum of 2 quarters · filed 2023-02-27 | $29.09M derived: sum of 3 quarters · filed 2023-02-27 | $29.01M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $18.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $26.90M derived: sum of 2 quarters · filed 2023-02-27 | $26.82M derived: sum of 3 quarters · filed 2023-02-27 | $26.10M 10-K · filed 2023-02-27 |
| 2020-09-30 | $8.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $8.05M derived: sum of 2 quarters · filed 2021-11-10 | $7.33M 10-Q · filed 2021-11-10 | $9.39M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$799.00K 10-Q · filed 2021-08-11 | $1.26M derived: sum of 3 quarters · filed 2022-02-28 | $388.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$723.00K 10-Q · filed 2021-05-11 | $1.33M derived: sum of 2 quarters · filed 2022-02-28 | $464.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.19M derived: sum of 2 quarters · filed 2022-02-28 | $868.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$871.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.19M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$319.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $1.27M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |